A few small placebo-controlled trials reported significant decreases in hepatic fat content and/or serum ALT levels by SGLT2i treatment in patients with T2DM and NAFLD (14, 19). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.